Data Readout

Cybin's CYB003 heads to Q4 2026 MDD readout after guiding six times

The Phase 3 APPROACH trial still targets a Q4 2026 topline readout after Cybin repeated that window through six disclosures, even as the registry's own completion date points to August.

By AppliedXLJuly 13, 2026Trial NCT06564818

Executive Summary

Cybin's lead depression program is approaching its first pivotal readout, a placebo-controlled trial built to test whether its deuterated psilocin molecule can move a standard depression rating scale in patients who have not responded to a prior antidepressant.
The sponsor has repeated the same quarterly window across six public updates over nearly a year, even though the trial's own registry completion date runs earlier than that window, a gap that bears watching rather than a delay.
No other psilocin-class or same-mechanism trial has reached a same-drug comparator stage in this indication, leaving the readout as the first pivotal data point for this specific molecular approach in adjunctive MDD, even as more than a dozen other mechanisms compete for the same patient population.
A separation from placebo on the primary endpoint would be the first pivotal validation of Cybin's deuteration approach to psychedelic dosing; a null or marginal result would leave the mechanism unproven heading into the company's second pivotal trial.

The trial

APPROACH (NCT06564818) is a randomized, placebo-controlled Phase 3 trial testing CYB003, a deuterated psilocin analog, as an adjunctive treatment in adults with moderate-to-severe major depressive disorder who have had an inadequate response to a single antidepressant. The trial enrolls 220 participants across roughly 45 U.S. sites and uses the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated depression severity measure, as its lone primary endpoint, with four secondary measures including the Beck Depression Inventory and a quality-of-life questionnaire. The design randomizes patients to CYB003 or placebo, which sets up a controlled test of whether the drug's effect on MADRS separates from expectancy and placebo response, a common challenge for psychedelic-assisted trials given their perceptible dosing experience. NCT06564818

Probability of Success

Endpoint Met86%

Completes86%

Clinical Significance24%

Regulatory89%

Timing guidance

Cybin has repeated its Q4 2026 topline guidance across six separate disclosures dated from September 2025 through June 2026, after initially guiding to a full-year 2026 window and then narrowing to the second half of 2026. The trial's own registry primary completion date sits at August 1, 2026, which falls before the start of the company's stated Q4 2026 readout window, a divergence between the two disclosed dates rather than a confirmed delay. That primary completion date was itself revised once, moving from March 1, 2026 to August 1, 2026 in a change recorded September 3, 2025, a five-month shift in the registry record. Cybin+1

Protocol conduct

Outside of that single completion-date change, APPROACH has been amended sparingly. The trial has carried a status change to Recruiting in November 2024 and two eligibility-criteria modifications since inception, and it retains a Stable protocol designation with roughly one registry change event per year. Enrollment has held flat at its original target of 220 participants with no growth or contraction recorded, consistent with a trial proceeding on its original design. NCT06564818

The competitive field

The adjunctive-MDD field carries a broad mix of small-molecule mechanisms in Phase 2 and Phase 3, including NMDA-modulating agents such as esketamine and dextromethorphan combinations, kappa-opioid antagonists such as navacaprant and icalcaprant, an AMPA-receptor modulator (osavampator) from Neurocrine Biosciences, and other 5-HT2A-active compounds such as D-Cycloserine and DT120. None of these programs shares CYB003's specific psilocin-analog chemistry, and no same-drug or same-mechanism trial in this indication has yet posted a resolved primary-endpoint outcome, so APPROACH stands as the first pivotal test of a deuterated psilocin approach to adjunctive MDD rather than a readout that can be benchmarked against a settled base rate for this exact mechanism. Cybin's second Phase 3 trial in the same program, EMBRACE (NCT06793397), remains in progress and is not yet available as a corroborating data point. NCT06564818

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.